Close Menu

NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.

The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.